A contested federal move to widen access to unproven peptides led the day's health news, joined by an Ebola case in Nigeria, a major CTE study and new research on targeted cancer therapy. The items span drug policy, outbreak response and biomedical science.
Peptide policy shift
The Trump administration posted a policy, first reported by AP, that lets compounding pharmacies dispense combinations of six unproven peptides, including BPC-157 and TB-500, without FDA action. Health Secretary Robert F. Kennedy Jr.'s department spearheaded the change; FDA scientific staffers had little input and opposed it, AP reported, and Bloomberg called it a temporary plan.
Reported by Philadelphia Inquirer
Reported by MarketWatch.com - Top Stories
Reported by Scientific American Content: Global
Ebola patient evacuated
The New York Times reported that Nigeria's Ebola patient was evacuated more than a week after the country's first case was reported. Investigators were still pressing for answers about the infection.
Reported by The New York Times
CTE in NFL players
Nearly three-quarters of NFL players who died during a recent 15-year period had CTE, a new study in JAMA Network Open found, The Boston Globe reported. The study included players whose brains were not donated and aimed to refine an earlier estimate.
Reported by Boston Globe
Targeted cancer carriers
Carnegie Mellon University researchers developed a low-cost way to repurpose cells' natural packages into drug carriers that deliver treatments directly to cancer cells, Phys.org reported. The approach could improve effectiveness and reduce side effects.
Reported by Phys.org - latest science and technology news stories
ZYNLONTA updates in Japan
Financial Times reported that ADC Therapeutics announced updates about its drug ZYNLONTA in Japan.
Reported by Financial Times
Checked
11 claims in this story checked against 7 sources: 4 supported.
Show each claim
- SupportedRFK Jr. eased access to unproven peptides despite opposition from FDA scientists.Boston Globe: “RFK Jr. eases access to unproven peptides despite opposition from FDA scientists.”
- SupportedThe administration’s move allows compounding of six peptides under a temporary plan."site:bloomberg.com when:1d" - Google News: “US to Allow Compounding of Six Peptides in Temporary Plan - Bloomberg.”
- Partly supportedThe policy allows combinations of the six peptides, including BPC-157 and TB-500, without FDA action.Scientific American Content: Global: “RFK, Jr., loosens restrictions for six popular peptides, bypassing the FDA.”
- Not in the sourcesThe policy was first reported by AP.Philadelphia Inquirer: “RFK Jr. eases access to unproven peptides despite opposition from FDA scientists.”
- Partly supportedFDA scientific staff had little input into the change and opposed it, according to AP.Boston Globe: “RFK Jr. eases access to unproven peptides despite opposition from FDA scientists.”
- Partly supportedNigeria’s Ebola patient was evacuated more than a week after the country’s first case was reported.NYT > World News: “Nigeria’s Ebola Patient Evacuated as Investigators Press for Answers.”
- SupportedInvestigators were pressing for answers about the infection.NYT > World News: “Nigeria’s Ebola Patient Evacuated as Investigators Press for Answers.”
- Partly supportedNearly three-quarters of NFL players who died during a recent 15-year period had CTE, according to a new JAMA Network Open study.Boston Globe: “Nearly 75 percent of NFL players who died in recent years suffered from CTE, a major new study finds.”
- Not in the sourcesThe CTE study included players whose brains were not donated and aimed to refine an earlier estimate.Boston Globe: “Nearly 75 percent of NFL players who died in recent years suffered from CTE, a major new study finds.”
- Partly supportedCarnegie Mellon researchers developed a low-cost way to repurpose cells’ natural packages as drug carriers that deliver treatment directly to cancer cells, potentially improving effectiveness and reducing side effects.Phys.org - latest science and technology news stories: “Customizable DNA labels can selectively guide drug carriers to cancer cells.”
- SupportedADC Therapeutics announced updates about ZYNLONTA in Japan."site:ft.com when:1d" - Google News: “ADC Therapeutics Announces ZYNLONTA® Updates in Japan - Financial Times.”
